PDC-TREM Inhibitors
PDC-TREM inhibitors belong to a class of chemical compounds that specifically target and modulate the activity of the triggering receptor expressed on myeloid cells (TREM) family, which plays a pivotal role in the innate immune response. The TREM family consists of cell surface receptors that are primarily expressed in myeloid cells, such as monocytes, macrophages, and dendritic cells. These receptors, particularly TREM-1 and TREM-2, are involved in the amplification and regulation of inflammatory signals. PDC-TREM inhibitors are designed to interact with these receptors to modulate their activity. They are typically small molecules that can bind to the extracellular domain of TREMs, thereby affecting the receptor's ability to engage with its ligands or with adaptor proteins that propagate intracellular signaling.
The design of PDC-TREM inhibitors incorporates structure-activity relationship (SAR) knowledge to enhance their selectivity and efficacy. By altering specific functional groups or molecular frameworks within these inhibitors, chemists can fine-tune their interaction with TREM receptors. The chemical characteristics of PDC-TREM inhibitors, such as solubility, stability, and permeability, also play a crucial role in their interaction with the TREM receptors. Advanced techniques like X-ray crystallography, molecular docking, and computational modeling are often employed to predict and improve the binding affinity of these inhibitors. Through such precise molecular interactions, PDC-TREM inhibitors can influence the receptor's conformation or block its association with other signaling molecules, thereby modulating the downstream signaling pathways initiated by TREM activation. The intricate balance between the potency of these inhibitors and their selectivity towards particular members of the TREM family is critical for their functional profiles.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor. By blocking EGFR, it prevents downstream signaling that may be crucial for the activation and function of PDC-TREM in cells that rely on EGFR signaling for activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a specific mTOR inhibitor, which in turn can lead to the downregulation of protein synthesis and cell proliferation, processes that could be vital for the functional activity of PDC-TREM. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. PI3K is part of a signaling pathway involved in cell growth and survival, which might be essential for the activity of PDC-TREM. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of the ERK pathway. This pathway can be implicated in the regulation of various proteins, potentially including PDC-TREM. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which could affect the activation state or expression of PDC-TREM if it is regulated by stress response pathways involving p38 MAPK. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor which may affect various signaling pathways that could regulate PDC-TREM activity, especially if those pathways involve receptor tyrosine kinases. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may influence the signaling pathways that regulate the cellular functions where PDC-TREM is involved. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 selectively inhibits NUAK family kinase 1 (NUAK1), which could indirectly lead to the inhibition of PDC-TREM if it is part of cellular processes involving energy metabolism and stress response. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
BMS-345541 is a selective inhibitor of the IκB kinase (IKK), which can modulate the NF-κB pathway. If PDC-TREM is regulated by NF-κB signaling, this compound could lead to its inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src-family kinase inhibitor that could impact various cellular pathways and might have an indirect effect on PDC-TREM activity if it is associated with signaling cascades regulated by Src kinases. | ||||||